Oncolys Out-Licenses Phase II HIV Drug to Bristol-Myers Squibb
By Heather Cartwright
Pharma Deals Review: Vol 2011 Issue 1 (Table of Contents)
Published: 10 Jan-2011
DOI: 10.3833/pdr.v2011.i1.1418 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Bristol-Myers Squibb has entered into a global licensing deal with Oncolys BioPharma, a privately held Japanese biotech, for Festinavir®, a once-daily, orally available nucleoside reverse transcriptase inhibitor (NRTI) in Phase II development for HIV...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS